Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Del Giglio (2013): Purified Dry Extract of Paullinia cupana (Guarana) (PC-18) for Chemotherapy-Related Fatigue in Patients with Solid Tumors: An Early Discontinuation Study  + (Absent at follow-up after randomization)
• Del Giglio (2013): Purified Dry Extract of Paullinia cupana (Guarana) (PC-18) for Chemotherapy-Related Fatigue in Patients with Solid Tumors: An Early Discontinuation Study  + (Absent at follow-up after randomization)

• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Adverse Events n=13 Withdrawn by investigator n=1 Lack of efficacy n=1 Died during treatment n=9)
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Adverse Events n=21 Withdrew consent n=2 Withdrawn by investigator n=1 Lack of efficacy n=1 Died during treatment n=23 Died post-treatment but before follow-up n=8 Died post follow-up n=3)
• Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain  + (Adverse event (n=10); consent withdrawal (n=1); other (n=1))
• Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain  + (Adverse event (n=3); consent withdrawal (n=2); other (n=3))
• Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain  + (Adverse event (n=7); consent withdrawal (n=2); sponsor decision (n=1); protocol violation (n=1); other (n=2))
• Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy  + (Bad adherence)
• Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy  + (Bad compliance to protocol)
• Ryan et al. (2011): Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients  + (Baseline: 1 - Began coumadin, 1 - Gastroin … Baseline:</br>1 - Began coumadin, 1 - Gastrointestinal, 1 - Low platelets, 1 - Treatment change, 1 - Other medical, 6 - Changed mind, 5 - Incomplete forms, 1 - Ineligible</br></br></br>Study Cycle 2: </br></br>2 - Chemotoxicity, 9 - Gastrointestinal, 1 - Low platelets, 5 - Off chemotherapy, 7 - Treatment change, 1 - Treatment delay, 5 - Other medical, 13 - Changed mind, 1 - Lost medication, 5 - Incomplete forms 1 - Lost medication, 5 - Incomplete forms)
• Ryan et al. (2011): Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients  + (Baseline: 1 - Began coumadin, 2 - Chemoto … Baseline: </br>1 - Began coumadin, 2 - Chemotoxicity, 2 - Gastrointestinal, 1 - Low platelets, 3 - Off chemotherapy, 1 - Treatment delay, 1 - Other medical, 5 - Changed mind, 2 - Incomplete forms</br></br></br>Study Cycle 2: </br></br>1 - Bleeding, 5 - Chemotoxicity, 7 - Gastrointestinal, 3 - Low platelets, 5 - Off chemotherapy, 3 - Treatment change, 5 - Treatment delay, 1 - Low WBC, 5 - Other medical, 10 - Changed mind, 4 - Incomplete forms, 1 - Deceasedd mind, 4 - Incomplete forms, 1 - Deceased)
• Ryan et al. (2011): Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients  + (Baseline: 1 - Began coumadin, 2 - Chemoto … Baseline: </br>1 - Began coumadin, 2 - Chemotoxicity, 2 - Gastrointestinal, 1 - Off chemotherapy, 5 - Other medical, 11- Changed mind, 3 - Incomplete forms</br></br></br>Study Cycle 2: </br></br>3 - Chemotoxicity, 5 - Gastrointestinal, 1 - Low platelets, 3 - Off chemotherapy, 1 - Radiation therapy, 1 - Treatment change, 2 - Treatment delay, 1 - Disease progression, 5 - Other medical, 15 - Changed mind, 1 - Drug incorrectly given, 1 - Lost medication, 10 -Incomplete forms 1 - Lost medication, 10 -Incomplete forms)
• Ryan et al. (2011): Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients  + (Baseline: 1 - Bleeding, 1 - Chemotoxicity … Baseline: </br>1 - Bleeding, 1 - Chemotoxicity, 1 - Gastrointestinal, 3 - Off chemotherapy, 2 - Other medical, 14 - Changed mind, 1 - Incomplete forms</br></br></br>Study Cycle 2: </br></br>1 - Bleeding, 4 - Chemotoxicity, 5 - Gastrointestinal, 2 - Low platelets, 2 - Off chemotherapy, 5 - Treatment change, 1 - Treatment delay, 1- Disease progression, 7 - Other medical, 7 - Changed mind, 2 - Drug incorrectly given, 6 - Incomplete formsug incorrectly given, 6 - Incomplete forms)
• Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial  + (Before randomization: n=4 cancelled, n=3 ineligible During study: n=11 refused further treatment, n=8 adverse events, n=2 alternate treatment, n=2 other medical problems, n=6 other reasons)
• Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial  + (Before randomization: n=7 cancelled, n=4 ineligible During study: n=18 refused further treatment, n=3 adverse events, n=4 alternate treatment, n=4 other medical problems, n=3 other reasons, n=1 died on study)
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (Before treatment: - consent withdrawn (n=2) - referred for treatment at another hospital (n=1) - inability to swallow a capsule (n=1) After treatment (but excluded from analysis): - protocol violation (n=1) - consent withdrawn (n=2))
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (Before treatment: - consent withdrawn (n=1) - referred for treatment at another hospital (n=1) After treatment (but excluded from analysis): - consent withdrawn (n=5))
• Henning et al. (2015): Randomized Clinical Trial of Brewed Green and Black Tea in Men With Prostate Cancer Prior to Prostatectomy  + (Caffeine reactions (n=2); surgery postponed (n=2); unrelated death (n=1); tea volume too large (n=3), stomach distress (n=1))
• Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial  + (Could not swallow capsules n = 1 Refused to swallow capsules n = 1)
• Lyckholm et al. (2012): A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders  + (Death (non–study related) (n=4), cancer treatment discontinued (n=4), toxicity (diarrhea, abdominal pain, cramps, diaphoresis) (n=2), pill burden (n=2), family member asked the patient to withdraw consent (n=1), and no reason given (n=2))
• Lyckholm et al. (2012): A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders  + (Death (non–study related) (n=4), cancer treatment discontinued (n=4), toxicity (diarrhea, abdominal pain, cramps, diaphoresis) (n=2), pill burden (n=2), family member asked the patient to withdraw consent (n=1), and no reason given (n=2))
• Lian et al. (2014): Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study  + (Death due to advanced cancer on day 5)
• Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial  + (Death due to cancer)
• Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial  + (Death due to cancer)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Death due to progression)
• Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation  + (Death n=1, Disease progression n=2)
• Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results  + (Death n=1, disease progression n=1)
• Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results  + (Death n=2, disease progression n=1)
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (Did not complete salivary dosimetry measurements)